Close Menu

product launch

NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.

The company launched the MassArray System with Chip Prep Module in Europe for general IVD use, targeting hospitals and laboratories. 

The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.

Diploid hopes to lighten the workload of clinical geneticists drowning in next-generation sequencing data.

Dubbing itself a "telegenomics company," San Francisco startup Genome Medical announced the launch this week of its genetic consultation services offering.

The telegenomics startup will use the proceeds to support the rollout of its genetic consultation services. A pilot version of the services was launched last fall.

Roche's Bluetooth-enabled meter gives patients the option to bypass frequent trips to the clinic in favor of doing anticoagulation testing at home.   

The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.

The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.

The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.

Pages

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.